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Abstract: Neuropsychiatric symptoms occur in a number of neurological fatigue-related 
conditions including multiple sclerosis (MS), Parkinson’s disease (PD), amyotrophic lateral 
sclerosis (ALS), and chronic fatigue syndrome (CFS). These conditions have been attributed 
variably to neuroinﬂ  ammatory and neurodegenerative processes. While autoimmune pathology, 
at least in part, has long been suspected in these conditions proof has been elusive. Autoimmune 
pathomechanisms affecting the blood–brain barrier (BBB) or blood–spinal barrier (BSB) may 
predispose the BBB/BSB to ‘leakiness’ and be a precursor to additional autoimmune events 
resulting in neuroinﬂ  ammatory or neurodegenerative processes. The aim of the paper is to postulate 
immunopathology of the cerebrospinal perivascular compartment involving certain vasoactive 
neuropeptides, speciﬁ  cally pituitary adenylate cyclase-activating polypeptide (PACAP) and 
vasoactive intestinal peptide (VIP), in the etiology of certain neuropsychiatric fatigue-related 
conditions such as MS, ALS, PD, and CFS. Vasoactive neuropeptides (VNs) such as PACAP 
and VIP have critical roles as neurotransmitters, vasodilators including perfusion and hypoxia 
regulators, and immune and nociception modulators. PACAP and VIP are widely distributed in 
the central nervous system (CNS) and have key roles in CNS blood vessels including maintaining 
functional integrity of the BBB and BSB. Autoimmunity affecting these VNs would likely have 
a detrimental effect on BBB and BSB functioning arguably predisposing to further pathological 
processes. Virchow–Robin spaces (VRS) are perivascular compartments surrounding small 
vessels within the CNS which contribute to the BBB and BSB integrity and contain PACAP and 
VIP receptors. Autoimmunity of these receptors would likely affect BBB and VRS function and 
therefore may contribute to the etiology of these conditions by affecting CNS and immunological 
homeostasis, including promoting neuropsychological symptomatology. PACAP and VIP, as 
potent activators of adenylate cyclase (AC), have a key role in cyclic adenosine monophosphate 
(cAMP) production affecting regulatory T cell (Treg) and other immune functions. Phosphodi-
esterase enzymes (PDEs) catalyze cAMP and PDE inhibitors (PDEIs) maintain cAMP levels and 
have proven and well known therapeutic beneﬁ  t in animal models such as experimental allergic 
encephalomyelitis (EAE). Therefore PDEIs may have a role in therapy for certain neuropsychiatric 
fatigue-related conditions.
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Introduction
Neuropsychiatric symptoms occur in a number of neurological fatigue-related conditions 
including multiple sclerosis (MS),1 Parkinson’s disease (PD),2 amyotrophic lateral Neuropsychiatric Disease and Treatment 2009:5 82
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sclerosis (ALS)3 and chronic fatigue syndrome (CFS).4 While 
autoimmune pathology, at least in part, has long been suspected 
in these conditions proof has been elusive. The present paper 
asserts a provocative hypothesis that autoimmune pathomecha-
nisms affecting the blood–brain barrier (BBB) or blood–spinal 
barrier (BSB) may predispose the BBB/BSB to ‘leakiness’ and 
be a precursor to additional autoimmune events resulting in neu-
roinﬂ  ammatory or neurodegenerative processes, compounded 
possibly on a genetically susceptible background or exposure 
to environmental factors.
The paper examines the potential role for vasoactive 
neuropeptides (VNs) such as pituitary adenylate cyclase-
activating polypeptide (PACAP) and vasoactive intestinal 
peptide (VIP) in the possible autoimmune etiology of these 
disorders through effects on the blood–brain/spinal barriers 
(BBB/BSB) whereby neuropsychiatric symptomatology may 
occur. PACAP and VIP, as potent activators of adenylate cyclase 
(AC), have a key role in cyclic adenosine monophosphate 
(cAMP) production affecting BBB/BSB function along with 
regulatory T cell (Treg) and other immune functions.
Phosphodiesterase enzymes (PDEs) catalyse cAMP and 
PDE inhibitors (PDEIs) maintain cAMP levels and have 
proven and well known therapeutic beneﬁ  t in animal models 
such as experimental allergic encephalomyelitis (EAE). 
Therefore PDEIs may have a role in therapy for certain 
neuropsychiatric fatigue-related conditions.
Functions of PACAP and VIP
PACAP and VIP are widely distributed in the central (CNS) 
and peripheral (PNS) including autonomic (ANS) nervous 
systems and peripheral tissues including heart, lung, pan-
creas, adrenal gland, gonads, and gastrointestinal tract as 
well as immune cells and lymphatic system.5,103 PACAP and 
VIP have critical roles as neurotransmitters, vasodilators 
including perfusion and hypoxia regulators, and immune and 
nociception modulators. They have key roles in blood vessels 
in the CNS84 and VIP is associated with maintaining functional 
integrity of the BBB.83 PACAP and VIP inﬂ  uence regulatory 
T cell (Treg)29 and other immune functions. Their role as anti-
inﬂ  ammatory modulators is of particular interest89 considering 
the implications for loss of immune and inﬂ  ammatory regula-
tion should they fail, for example through autoimmunity of 
their receptors. PACAP and VIP are potent activators of AC 
and thus have a key role in cAMP production.
Virchow–Robin spaces (VRS) are perivascular com-
partments surrounding small vessels within the CNS which 
contribute to BBB and BSB integrity and modulate immune 
responses.90 VRS contain microglia and these cells are known 
to be inﬂ  uenced by PACAP and VIP in immunoregulation.8 
Autoimmunity of these VNs or their receptors would be 
expected to affect BBB/BSB and VRS function and therefore 
may contribute to the etiology of neuropsychiatric-related 
neurodegenerative and other conditions by affecting CNS 
and immunological homeostasis.
Autoimmunity as an etiology in MS, ALS, PD, and CFS 
remains controversial. While autoimmunity is reasonably well 
established in MS,88 an autoimmune etiology in PD,85 which 
may involve the BBB,86 and ALS87 is only just emerging. 
Autoimmunity affecting PACAP and VIP has been postulated as a 
possible contributing factor in MS and ALS,79 PD80 and CFS.81
Role of PACAP and VIP 
in the blood–brain/blood–spinal 
barrier
The multiple functions of PACAP and VIP impact on main-
taining BBB/BSB function. Moreover PACAP and VIP have 
speciﬁ  c and complex roles in the CNS including high level 
neurological functioning such as memory and learning.6 
PACAP and VIP have a well described neuroprotective role7 as 
well as being inﬂ  ammatory mediators in microglial activation,8 
therefore their failure may be linked to neuroinﬂ  ammatory and 
other disease processes in the BBB/BSB and the CNS.
PACAP and VIP exert potent effects in metabolism as 
they have a vital role in cAMP production and regulation 
through AC activation. Immunological dysregulation of vital 
biochemical and/or epigenetic mechanisms affecting PACAP 
and VIP resulting in down-regulation of cAMP are possible 
pathways by which disease entities become manifest. Their 
role along with other neurotrophic factors,9 in maintaining 
cAMP levels10 are important for maintaining the integrity of 
the BBB and the BSB.
Conditions such as MS, PD, and ALS are increasingly 
being investigated for possible disruption of the BBB or 
the BSB.11–13 Zlokovic107 asserts BBB breakdown due to the 
disruption of the tight junctions may initiate and or contribute 
to a “vicious circle” of disease process resulting in progres-
sion synaptic and neuronal dysfunction and loss in disorders 
including PD, ALS, and MS. The BBB and the BSB are the 
main barriers between the brain and spinal cord parenchyma 
and the intravascular compartment and are therefore impor-
tant in keeping immune hydrophilic macromolecules and 
neuroactive hormones from interfering with brain and spinal 
neurological processes. Generally the CNS parenchyma does 
not express MHCII molecules consequently the CNS has long 
been regarded as an immune privileged site. However certain 
cells such as pericytes and microglia within the BBB and BSB Neuropsychiatric Disease and Treatment 2009:5 83
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are able to express MHCII molecules on activation and initiate 
T helper cell (Th4) immunological responses.66 PACAP and 
VIP suppress the expression of MHCII molecules102 and 
this likely has an important role in maintaining the immune-
protected status of the CNS through maintaining the integrity 
of the BBB/BSB. Disruption of BBB and BSB are well known 
in certain pathological states, for example, injury and inﬂ  am-
mation and this disruption may involve VRS.
VRS contain interstitial ﬂ  uid and, while some functional 
contact with sub-arachnoid spaces may occur for solute 
exchange, there is doubt whether they contain CSF.14 VRS 
have important connections with lymphatic drainage of the 
head and neck15 as well as having intricate pial relations and 
providing a surface for activity of neuropeptides, hormones 
and cytokines. Pial cells may have a role in protecting the 
brain from exogenous catecholamines16 and VRS may 
have a complex role in leukocyte recruitment across, and 
maintenance of the BBB.17 They are a likely site for antigen 
presentation and antigen presenting cell (APC) engagement 
and MHCII recognition. Perivascular microglia in the VRS 
undertake APC recognition in the CNS.18 Hence it is pos-
sible CNS inﬂ  ammation may be initiated within the CNS 
and not in the periphery alone. As PACAP and VIP and their 
receptors are located throughout the CNS parenchyma and 
vasculature they not only serve a role in immunomodulation 
they could also serve as antigens which might be subject 
to autoimmunity. Whether VN- or VN receptor-activated 
autoimmune Th cells arise from the periphery and undertake 
autoimmune processes in CNS and other sites is unknown 
and is an important question for further research.
PACAP and VIP are known to have neuroprotective 
effects through hypoxia protection on passage through the 
BBB19 via a transport mechanism which enables the intact 
peptides to enter the parenchymal space of the brain.20 Addi-
tionally PACAP and VIP have protective effects on neurons 
and glial cells.21 These VNs therefore may have a signiﬁ  cant 
role in blood BBB/BSB function and likely assist in immune 
regulation of VRS in the brain and spinal cord. The present 
paper asserts that, in view of the many vital roles of PACAP 
and VIP in CNS neuroregulatory and immunological func-
tion including BBB function, autoimmunity to these VNs or 
their receptors will have signiﬁ  cant effects on homeostasis 
possibly resulting in neuropsychiatric symptoms.
PACAP and VIP in 
neuroimmunological dysregulation
PACAP and VIP exert antiinﬂ  ammatory activities and loss of 
their function, for example through autoimmune compromise, 
could become manifest as unmodulated activation of immune 
responses. Hence effects of VN autoimmunity may extend 
beyond the BBB and BSB and a complex multisystem expla-
nation for certain neuropsychiatric fatigue-related conditions 
is possible.
PACAP and VIP exert influence over inflammatory 
control mechanisms including inﬂ  uencing Th1 to Th2 shift 
and suppression of proinﬂ  ammatory activity through the 
PKA/cAMP pathway.23 For example tumor necrosis factor 
alpha (TNF-α) has a reciprocal modulating relationship with 
cAMP in vascular dysfunction involving endothelial cells24 
and this may prove to be an analogous mechanism in VRS. 
Implications for the BBB/BSB functioning are important as 
the VRS has been identiﬁ  ed as a location for immunoreactive 
lymphocytes in penetration of neuronal parenchyma.25 Also 
VIP has been identiﬁ  ed in connection with neuronal function 
and VRS, which suggests that VIP may have a regulatory 
function associated with vasodilatation.26 We assert that 
important immunoregulation occurs in perivascular spaces 
and VRS and that this may involve PACAP/VIP regulation. 
Many regulatory and antiinﬂ  ammatory functions of  PACAP 
and VIP are dependent on the Th2-directed cytokines93 
eg, interleukin-10 (IL-10) and IL-4 and these could be com-
promised in PACAP/VIP failure. Moreover ‘leakiness’ in the 
BBB and BSB may initiate, or encourage development of 
relapses in, neurological conditions such as MS.27
Regulatory T cells (Tregs) function to control autoreac-
tive T cells in the periphery28 and possibly within the brain 
parenchyma. Treg function is substantially inﬂ  uenced by 
these VNs29 and they may also have inﬂ  uence over Th17 
direction.30 Loss of Treg function in VRS will therefore have 
signiﬁ  cant implications for inﬂ  ammatory control. Moreover 
Th17 development occurs under IL-6 and transforming 
growth factor beta (TGF-β) inﬂ  uence31 and this may be a 
key switching point from a protective Treg phenotype to an 
autoimmune Th17 phenotype. Certainly Th1 and Th17 ratios 
are important in brain and spinal inﬂ  ammation regulation.32 
Further, autoreactive Th cells within the CNS are likely to 
be critical determinants of disease development.
Interestingly a number of seemingly unrelated disorders 
may be implicated in postulated PACAP/VIP autoimmune 
pathology. For example, Crohn’s disease (CD) and MS are 
inﬂ  ammatory disorders with known Th1-directed cytokines 
and loss of Foxp3 Treg function.33,34 In one study in MS 
patients Treg numbers were unchanged but their function 
may have been diminished.92 As VRS have important roles in 
controlling macrophage and perivascular inﬁ  ltrates in MS,35 
VRS immunological function in relation to VNs becomes Neuropsychiatric Disease and Treatment 2009:5 84
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of considerable interest. Complement-ﬁ  xing myelinolytic 
antigens have been identiﬁ  ed in the VRS in early MS,36 
which indicates the possible involvement of VRS in immune 
activity. However autoimmunity directed at VN guanine 
nucleotide protein-coupled receptors (GPCRs) is currently 
unproven and loss-of-function autoimmunity to GPCRs gen-
erally is not well documented,22 although parallels exist with 
other conditions eg, Sjogren’s syndrome which has T cell 
and/or B cell antibody targeting of acetylcholine GPCRs.37
The role of PACAP and VIP in linking the innate and 
acquired immune systems38 suggests there would be signiﬁ  cant 
effects on immunological and neurological homeostasis if 
they are compromised and include their complex inﬂ  uences 
on inﬂ  ammatory regulation involving microglia.105 As noted 
above, macrophages and microglia in VRS express MHC 
class II molecules, albeit in low levels constitutively, and 
interact with lymphocytes from the blood in initiating and 
promoting immune responses to foreign antigens in the brain. 
However not all inﬂ  ammatory events within the CNS lead to 
MS.104 Nevertheless, sites deﬁ  cient in the BBB include the 
subarachnoid space and pial surface, and circumventricular 
organs may be more prone to macromolecule penetration of 
CSF and this may have implications regarding autoimmune 
dysfunction within the CNS.39 Collections of macrophages may 
occur in VRS following trauma in a pro-inﬂ  ammatory context40 
and pathological dilatation of VRS may occur from a variety of 
causes including ischemia.41 These pathological features rely 
on PACAP/VIP protection to ameliorate their effects.
The distribution of VRS in anatomically speciﬁ  c locations 
implies that compromise of VRS will affect the functions of 
those anatomical locations. For example VRS located in the 
nucleus tractus solitarius in the dorsal medulla oblongata 
suggests that their compromise may have a role in impairing 
viscerosensory and autonomic functions.42 Capillary diver-
sity within the subfornical organ (SFO) and area postrema 
(AP) may function as low-resistance pathways for the rapid 
dispersion of blood-borne hormones inside their organ 
boundaries and this may have a role in regulation of blood 
pressure and body ﬂ  uids.43 Hence these functions linked 
to VRS microanatomy may be particularly susceptible to 
PACAP/VIP compromise.
Vascular compromise within the CNS, possibly as a 
result of PACAP/VIP compromise, may give rise to features 
consistent with certain forms of dementia. Fronto-temporal 
dementia (FTD) is a neurodegenerative disease in which a 
vascular component is suggested and immunoreactivity of 
Bax, a proapoptotic protein regulated in part by PACAP/
VIP in astrocytes, suggests a role for autoimmunity in the 
pathology of FTD.44 Astrogliosis in FTD corresponds with 
SPECT hypoperfusion, suggesting that astrocyte disruption 
may be related to disturbances of cerebral perfusion in FTD.45 
Cognitive dysfunction is associated with reduced cerebral 
blood ﬂ  ow in different types of dementia.46 Moreover VRS 
dilatation associated with microvessel abnormality may 
contribute to the diagnosis of vascular dementias.47 Changes 
in social behavior occur in cerebrovascular comprise and may 
result from an FTD-like syndrome.48 Similarly, reduction in 
cortical blood ﬂ  ow has been identiﬁ  ed in CFS patients;49,50 
however these ﬁ  ndings were not replicated in a study of twins 
with CFS.51 FTD however is recognized in ALS.91
Other mechanisms such as water channel function are 
inﬂ  uenced by PACAP/VIP. The astroglial water channel 
aquaporin (AQP4) is essential for the maintenance of BBB 
integrity.52 Antibodies to AQP4 have a highly speciﬁ  c role 
in neuromyelitis optica (NMO) and characteristically bind 
to cerebral microvessels, pia mater and VRSs.53 Secretin is 
important for other aquaporin expression via vasopressin, 
secretin receptor-null mice for example have reduced renal 
expression of AQP2 and AQP4.54 Thus VIP impairment may 
inﬂ  uence water channel function. Additionally an association 
with VRS has been identiﬁ  ed supporting the view that corti-
cal nerve cells release VIP in the perivascular space during 
periods of activity and thus contribute to local vasodilatation 
associated with neuronal function. There is an important 
relationship whereby ATP over-expression has a down-
regulatory impact on AQP4 expression.55 Adenylate cyclase 
compromise could have an impact on ATP levels by failure 
to convert to cAMP, arguably maintaining elevated levels of 
ATP with adverse consequences for AQP4 function.
Treatment in PACAP/VIP postulated 
autoimmune neuropsychiatric 
fatigue-related disorders
Receptors for PACAP and VIP exhibit a number of sub-
types which are located in speciﬁ  c anatomical locations. 
Autoimmunity may affect these different sub-types in 
different anatomical regions. Thus it may be possible that 
VN receptor subtypes speciﬁ  c for the substantia nigra (SN) 
may be involved in, for example, PD. PACAP activates 
receptors of PAC1R, VPAC1R, and VPAC2R families, and 
PACAP has been identiﬁ  ed widely in the brain including the 
SN as well as in other organs and blood cells.56 Moreover, 
PACAP has been shown to be effective in treatment in rat 
models of PD.57 Both PACAP and VIP have neuroprotec-
tive effects in PD models by inhibiting the production of 
inflammatory mediators.58 PACAP specifically protects Neuropsychiatric Disease and Treatment 2009:5 85
Vasoactive neuropeptide immunopathology in blood–brain/blood–spinal barrier
against the neurotoxicity induced by rotenone59 as well as 
protecting against oxidative stress-induced apoptosis.60 In 
a murine model for PD, Delgado and Ganea61 note that the 
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) activates microglia and promotes dopaminergic 
neuronal loss. These pathologies are signiﬁ  cantly decreased 
by VIP thus suggesting that VIP may be useful in treatment 
of neuropathological conditions such as PD. Conversely these 
ﬁ  ndings might suggest that a defect in speciﬁ  c PACAP/VIP 
function could act adversely on SN cells and, perhaps in 
concert with other environmental factors, contribute to a 
clinical presentation consistent with PD.
PACAP/VIP are critical for neuronal survival. In a 
series of ALS patients, CSF levels of VIP were found to 
be signiﬁ  cantly lower compared with controls.62 VIP has 
demonstrated potent effects on neurite outgrowth in spinal 
cord cultures suggesting its use in treatment of ALS.63 
Interestingly Sun and colleagues64 noted impaired VIP receptor 
(VPAC2) production in activated T cells in MS patients, 
suggesting transcription irregularity at promoter regions of 
the VPAC2 gene. These ﬁ  ndings may be extremely important 
as more widespread impairment of VIP, if proven in patients 
with MS, may explain the manifestations associated with 
this condition. Also, in another paradigm, oligodendrocyte 
PACAP and VIP receptors 
(PAC1, VPAC1, VPAC2) 
Class II (Vasoactive neuropeptide) GPCR 
Blood brain barrier and Virchow–Robin spaces 
(pericytes, microglia) and other CNS, PNS, ANS    
Autoimmunity to VN GPCRs 
(eg, following infection and/or 
molecular mimicry)
Impaired adenylate cyclase  Inhibit cAMP 
breakdown
Diseases/syndromes
Multiple sclerosis 
Amyotrophic lateral sclerosis 
Parkinson’s disease 
Chronic fatigue syndrome
Functions of PACAP/VIP 
Inflammation modulation 
Neurotransmitter
Co-transmitter (for 
catecholamines and 
cholinergic neurotransmitters) 
Hypoxia regulation 
Memory/concentration
Brain plasticity 
CO, NO regulation 
Effects of VN GPCR 
autoimmunity
MHC II expression increased 
Th1/Th2/Th17 balance shift 
Treg/Foxp3 control impaired
cAMP 
Phosphodiesterase
inhibitors
eg, Rolipram, Ibudilast
Figure 1 Postulated effect of PACAP/VIP autoimmunity on blood–brain barrier and CNS predisposing to neuroinﬂ  ammation and/or neurodegeneration including potential 
treatment with phosphodiesterase inhibitors.
Abbreviations: ANS, autonomic nervous system; CO,  carbon monoxide; CNS, central nervous system; GPCR, G protein-coupled receptors; NO, nitric oxide; PACAP, pituitary 
adenylate cyclase-activating polypeptide;   VIP, vasoactive intestinal peptide;   VN, vasoactive neuropeptides.Neuropsychiatric Disease and Treatment 2009:5 86
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apoptosis is suggested as the earliest change leading to MS. 
Tissue injury may be ampliﬁ  ed over months or years as a 
result of oligodendrocyte cell death associated with myelin 
phagocytosis initiating local macrophage scavenger activity.65 
This paradigm is consistent with PACAP/VIP failure.
There are signiﬁ  cant treatment implications from this 
VN autoimmune hypothesis. As noted above, PACAP 
and VIP exert potent effects in metabolism as they have a 
vital role in cAMP production and regulation through AC 
activation. PDEs metabolise cAMP as a means of feedback 
regulation of cAMP levels. PACAP/VIP compromise could 
result in impaired AC activation and hence impaired cAMP 
production. Thus phosphodiesterase inhibitors (PDEIs), 
novel therapeutic substances used to promote cAMP levels106 
may have a role in treatment of VN autoimmune conditions. 
PDEIs have been identiﬁ  ed as a mechanism to modulate 
neuronal activity in psychiatric and neurodegenerative 
disorders.94
Drugs such as rolipram, a phosphodiesterase type 
4 inhibitor, activate cAMP-response element binding proteins 
(CREB) signalling as well as enhancing cAMP levels through 
impeding cAMP catabolism.67 Imipramine also appears to 
have a key role in cAMP metabolism and therefore may have 
a role in combination drug therapy68,69 as this pathway may 
share features with activity of PACAP and VIP as cAMP 
enhancers.
Rolipram was developed as an antidepression drug but has 
been found to have antiinﬂ  ammatory and immunoregulatory 
activities.70,71 Mediation of rolipram’s antiinﬂ  ammatory 
effects is suggested through modulation of antigen presenting 
functions of dendritic cells and lowering of MHC II 
expression. An IL-10-dependent mechanism is suggested 
in vitro72 but an IL-10-independent mechanism is suggested 
in vivo.77 Mediation of autoimmune protection in islet cells 
is associated with suppression of inducible nitric oxide 
synthase (iNOS) mRNA73 and suppression of macrophage 
activation along with NO suppression is noted in mouse 
peritoneal macrophages.74 Perhaps contrarily, NO genera-
tion might be a contributing factor to the therapeutic beneﬁ  t 
in EAE achieved by Rolipram in rats.78 However there is 
evidence that rolipram stabilises the endothelial junctions of 
the BBB/BSB to reduce permeability to inﬂ  ammatory cells 
and reduce EAE severity.96 The efﬁ  cacy of PDEIs in MS is 
being considered and clinical trials are indicated.97 Models of 
PD98–100 and ALS101 also suggest a role for PDEIs in treatment. 
Theoretically some of the pathology of these diseases may 
be reversible with PDEIs. Experimental models in EAE, for 
example, show promising results.95
Rolipram has a protective effect in experimental 
autoimmune neuritis associated with downregulation of 
interferon-gamma (IFN-γ) and inﬂ  ammatory chemokines 
as well as upregulation of IL-4 in the PNS.75 Unfortunately 
side-effects such as nausea, vomiting, and headache are 
reported suggesting the need for less side effect-inducing 
analogues in therapy76 and continuous administration may be 
necessary to sustain its therapeutic effect.77 However PDEIs 
have proven to be of beneﬁ  t in vitro and clinical trials in 
humans, particularly using more recent generation drugs, may 
be considered provided side effects are not a barrier.82
Conclusion
Certain neurological fatigue-related conditions such as 
MS, ALS, PD, and CFS often present with fatigue and 
other neuropsychiatric symptoms including memory and 
concentration loss, emotional lability, and confusion. 
Whether these conditions reﬂ  ect related neuroinﬂ  ammatory 
and neurodegenerative molecular pathology is speculative. 
However multisystem involvement including cerebrospinal 
effects of these conditions could be explained in part through 
PACAP and VIP compromise. In particular, cerebrovascular 
and spinovascular effects at the ultramicroscopic level 
involving BBB/BSB may contribute to these disorders. 
Compromise of PACAP and VIP or their receptors may 
have a role and should be the subject of further research. 
Evidence for compromise of these VN receptors at different 
levels including VN receptor mRNA, protein transcription, 
cellular migration and trafﬁ  cking, cell membrane localization 
and possible antibody or T cell targeting may provide an 
explanation for some of the etiology of these disorders. 
Alternatively, antagonist short-form variants of VNs 
themselves may exist through faulty protein manufacture 
and produce a similar clinical picture.
If PACAP and VIP do indeed fail, through autoimmunity 
of their receptors, MHCII molecules usually expressed at low 
levels in BBB, eg, in microglia/pericytes, and normally kept 
in check by PACAP and VIP, may be at risk of becoming 
overexpressed. This may be the initiating event for BBB/
BSB breakdown and subsequent neuroinﬂ  ammation and/or 
neurodegeneration in MS, PD, and ALS. Why CFS does not 
proceed to result in further demonstrable neurodegenerative 
pathology is not clear under this model although conﬁ  rma-
tory studies have not been done to date. The possibility that 
PACAP/VIP failure also leads to Treg impairment, possibly 
through impaired Foxp3 expression, is also yet to be inves-
tigated. Treg impairment has been described in MS patients 
suggesting possible PACAP/VIP failure.Neuropsychiatric Disease and Treatment 2009:5 87
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PDEs metabolize cAMP and serve to regulate cAMP 
levels. PACAP/VIP compromise will result in impaired AC 
activation and hence impaired cAMP production. Noting 
the cAMP-protecting effects of PDEIs there is evidence 
to suggest PDEIs may have a role in treatment for certain 
neuropsychiatric fatigue-related conditions.
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